Video blog: BOLERO-2 and Afinitor in breast cancer

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

While strolling through the woods, my eyes landed on a woodpecker, whose actions sparked a cancer analogy in my mind.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

When my wife was diagnosed with stage 3B melanoma, we decided to openly speak about our fears.